Samir Turk, MD
Cardiovascular Disease · Minot, NDNPI 1770657157
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,734 of the $5,573 with a category attached, or 67.0%. 18 manufacturers reported payments, led by Medtronic at 44.8% of the total.
Across 134 payments — averaging $41.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Janssen Research & Development, LLC$1K
- Boston Scientific$798
- Shockwave Medical, Inc$454
- W. L. Gore & Associates, Inc.$217
- Penumbra, Inc.$103
- plus $492 from 12 others
Across 168 payments — averaging $4590.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$519K
- CSL Behring$141K
- American Regent$43K
- Bayer$21K
- Boehringer Ingelheim International GmbH$20K
- Boehringer Ingelheim Pharma GmbH & Co.kg$20K
- plus $7K from 2 others
What the payments were for
- Travel & lodging$1,83933%
- Food & beverage$3,73467%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 41 | $2,498 |
| Janssen Research & Development, LLC | 10 | $1,011 |
| Boston Scientific | 35 | $798 |
| Shockwave Medical, Inc | 25 | $454 |
| W. L. Gore & Associates, Inc. | 3 | $217 |
| Penumbra, Inc. | 1 | $103 |
| Philips North America LLC | 2 | $78 |
| Edwards Lifesciences | 1 | $76 |
| AstraZeneca | 4 | $64 |
| Abbott | 1 | $48 |
| Abiomed | 2 | $44 |
| Pfizer | 2 | $41 |
| Atricure, Inc. | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Stryker | 1 | $24 |
| GE HealthCare | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| Angiodynamics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONYX FRONTIER$707
- TurboHawk$382
- Penumbra System$206
How this compares
$5,573 in reported general payments places this provider in the 65th percentile of 35 cardiovascular disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 537 | $446,963 |
| EntrestoSacubitril/Valsartan | 176 | $158,153 |
| OpsumitMacitentan | 12 | $152,391 |
| XareltoRivaroxaban | 171 | $107,431 |
| BrilintaTicagrelor | 47 | $27,458 |
| JardianceEmpagliflozin | 27 | $22,025 |
| Metoprolol Succinate | 645 | $11,279 |
| ClopidogrelClopidogrel Bisulfate | 509 | $7,039 |
| Flecainide Acetate | 81 | $3,933 |
| Midodrine Hcl | 28 | $3,816 |
| Rosuvastatin Calcium | 241 | $3,783 |
| Atorvastatin Calcium | 350 | $3,597 |
| Potassium Chloride | 121 | $3,451 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 139 | $2,867 |
| Nitroglycerin PatchNitroglycerin | 55 | $2,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $446,963537 claims |
| AstraZenecaBrilinta | $64 | $27,45847 claims |
| Boehringer IngelheimJardiance | $16 | $22,02527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 cardiovascular disease providers in North Dakota.
Other cardiovascular disease in Minot
- Beng Loong Isaac TeaMinot$42K
- Mir SublaMinot$5K
- Valentine ChikwenduMinot$3K
- Noah ChelliahGrand Forks$115K
- Hussain BasrawalaGrand Forks$40K
- Thomas HaldisFargo$37K
- Matthew GlogozaFargo$36K
- Mikhail KirnusGrand Forks$16K
- Timothy PansegrauBismarck$16K
- Jason GoFargo$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.